中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

奥曲肽联合加大补液量治疗肝硬化难治性腹水的效果观察

戈宏焱 李培霞 张洋洋 王丽丽 魏耀玲

引用本文:
Citation:

奥曲肽联合加大补液量治疗肝硬化难治性腹水的效果观察

DOI: 10.3969/j.issn.1001-5256.2018.01.020
详细信息
  • 中图分类号: R575.2

Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

  • 摘要:

    目的通过观察奥曲肽联合加大补液量对肝硬化难治性腹水的疗效,为临床提供新的诊疗思路。方法收集2016年2月-2017年5月就诊于内蒙古民族大学附属医院的肝硬化难治性腹水患者65例,随机分为对照组(n=31)和观察组(n=34)。对照组给予常规治疗;观察组在常规治疗的基础上给予奥曲肽0.6 mg,1次/12 h,持续泵入3 d后,改为0.2 mg,1次/8 h,皮下肌注,连续应用710 d,并加大补液量,其余治疗根据患者自身症状及机体耐受情况给予对症处理。观察治疗期间患者的生命体征、腹围、体质量及腹水消退时间,统计患者住院天数及并发症的发生率。计量资料组间比较采用t检验;计数资料组间比较采用χ2检验。结果观察组患者腹水消退时间及住院天数均短于对照组,差异均有统计学意义[(6.13±1.25)d vs(11.61±1.34)d,t=-4.06,P<0.001;(10.01±1.46)d vs(16.10±1.57)d,t=-7.65,P<0.001];腹围平均每天减少量、体质量平均每天减少量均高于对照组,差异均有统计学意义[(4.01±...

     

  • [1]ARROYO V, GINES P, GERBES AL, et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J].Hepatology, 1996, 23 (1) :164-176.
    [2]CHEN Y, ZHOU L.Research advances in treatment of cirrhotic ascites[J].J Clin Hepatol, 2016, 32 (6) :1069-1074. (in Chinese) 陈煜, 周莉.肝硬化腹水治疗的新进展[J].临床肝胆病杂志, 2016, 32 (6) :1069-1074.
    [3]SANGIOVANNI A, PRATI GM, FASANI P, et al.The natural history of compensated cirrhosis due to hepatitis C virus:a 17-year cohort study of 214 patients[J].Hepatology, 2006, 43 (6) :1303-1310.
    [4]GE JB, XU YJ.Internal Medicine[M].8th ed.Beijing:People's Medical Publishing House, 2013:419-428. (in Chinese) 葛均波, 徐永健.内科学[M].8版.北京:人民卫生出版社, 2013:419-428.
    [5]LIN PC, LIN YK, LI YB, et al.Advances in the treatment of cirrhotic ascites[J].Mod J Integr Tradit Chin West Med, 2014, 23 (29) :3299-3301. (in Chinese) 林培淳, 林勇凯, 李艺滨, 等.肝硬化腹水治疗进展[J].现代中西医结合杂志, 2014, 23 (29) :3299-3301.
    [6]OCHS A, ROSSLE M, HAAG K, et al.The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites[J].N Engl J Med, 1995, 332 (18) :1192-1197.
    [7]SINGHAL S, BAIKATI KK, JABBOUR II, et al.Management of refractory ascites[J].Am J Ther, 2012, 19 (2) :121-132.
    [8]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.
    [9]LIU HH, LUO SQ, FU JL, et al.Advances in the treatment of intractable cirrhotic ascites[J].J Pract Hepatol, 2011, 14 (4) :317-320. (in Chinese) 刘红虹, 罗生强, 福军亮, 等.肝硬化顽固性腹水的治疗新进展[J].实用肝脏病杂志, 2011, 14 (4) :317-320.
    [10]SCHRIER RW.Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy[J].N Engl J Med, 1988, 319 (17) :1127-1134.
    [11]FORTUNE B, CARDENAS A.Ascites, refractory ascites and hyponatremia in cirrhosis[J].Gastroenterol Rep (Oxf) , 2017, 5 (2) :104-112.
    [12]ZHANG JL, LIU JL, LI YG, et al.The treatment discussion of refractory ascites in the cirrhosis of the liver[J].J World Latest Med Inf, 2016, 16 (100) :52-53, 56. (in Chinese) 张俊立, 刘静丽, 李艳歌, 等.肝硬化难治性腹水的治疗探讨[J].世界最新医学信息文摘, 2016, 16 (100) :52-53, 56.
    [13]GUO LX.Clinical treatment in patients with liver cirrhosis refractory ascites[J].Chin Community Doct, 2016, 32 (35) :56, 58. (in Chinese) 郭丽仙.肝硬化难治性腹水的临床治疗观察[J].中国社区医师, 2016, 32 (35) :56, 58.
    [14]ZHANG GQ.An analysis of clinical therapies for cirrhotic ascites[J].Chin J Mod Drug Appl, 2017, 11 (3) :133-135. (in Chinese) 张桂芹.肝硬化腹水临床的治疗方法分析[J].中国现代药物应用, 2017, 11 (3) :133-135.
    [15]ZHU Q, JIANG XH, YI F, et al.The effects of octreotide on portal hemodynamics in patients with liver cirrhosis[J].Chin J Intern Med, 2004, 43 (1) :16-18. (in Chinese) 诸琦, 江晓华, 乙芳, 等.奥曲肽对肝硬化门脉血流动力学的影响[J].中华内科杂志, 2004, 43 (1) :16-18.
  • 加载中
计量
  • 文章访问数:  2380
  • HTML全文浏览量:  55
  • PDF下载量:  402
  • 被引次数: 0
出版历程
  • 出版日期:  2018-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回